Navigation Links
Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
Date:7/16/2009

SAN FRANCISCO, July 16 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed a private placement of shares of its common stock and warrants to purchase additional common stock for aggregate gross proceeds of approximately $3.4 million. Riverbank Capital Inc., a FINRA member broker dealer acted as the exclusive placement agent for the transaction.

"We are extremely pleased to have the completed this financing," said Joshua Kazam, Chief Executive Officer, "which we believe will provide us with sufficient capital to complete our Phase 2 clinical study of CD-NP in acute heart failure patients with mild to moderate renal insufficiency."

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration under such act and applicable state securities laws or an applicable exemption from those registration requirements. Nile has agreed to file a registration statement covering the resale of the shares issued in the private placement, including the shares issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas o
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
2. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
6. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
7. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
8. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
11. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 In an ... the UPMC Center for Health Security review the clinical ... can be used as bioweapons. The article, "Clinical Management ... today on the website of the New England ... Adalja, Eric Toner , and Tom Inglesby—review the ...
(Date:3/4/2015)... Mar. 04, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad ... can be objectively measured and evaluated as an ... well as pharmacological responses to a therapeutic intervention. ...
(Date:3/4/2015)... Proove Biosciences , a ... excited to announce the launch of their CME-accredited ... Management of Pain”. , The continuing medical education ... next year. The focus of the program is ... pain treatments, integrate appropriate pain management techniques, and ...
(Date:3/4/2015)... Follow us on LinkedIn ... fastest growing technologies in the life sciences industry. Growing ... driving growth in nucleic acid detection technologies like qPCR ... expressions will continue to benefit the qPCR and dPCR ... from pharma, biotech, food & beverage to animal feed, ...
Breaking Biology Technology:Latest Clinical Information On Bioterrorism Threats 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4
... 2012 Amgen (NASDAQ: AMGN ) and ... that the companies have entered into a definitive merger ... company founded in Germany with its research and development ... for $11 per share in cash. The transaction, which ...
... (NASDAQ: SQNM ) today announced the completion of ... stock, including 1,950,000 shares sold pursuant to the full exercise ... of the shares were offered by Sequenom at a price ... to Sequenom from this offering were approximately $62.0 million, before ...
... Corporation (NPC) and Sanford Wittels & Heisler, LLP, Counsel to ... resolve the nationwide Wage and Hour class action against NPC ... District of New York.  NPC has agreed ... up to 99 million dollars for eligible class members.  This ...
Cached Biology Technology:Amgen to Acquire Micromet 2Amgen to Acquire Micromet 3Amgen to Acquire Micromet 4Amgen to Acquire Micromet 5Amgen to Acquire Micromet 6Amgen to Acquire Micromet 7Amgen to Acquire Micromet 8Amgen to Acquire Micromet 9Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock 2Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock 3Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 2Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 3Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 4
(Date:2/5/2015)... 28, 2015 New Market Research ... Segment Forecasts To 2020 has Been Added to GrandViewReseach.com ... is expected to reach USD 5.10 billion by 2020, ... Inc. IR cameras help identify the site of tissue ... witness surging demand in medical imaging applications. They have ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... - A Global Market Overview" report to their offering. ... is to ensure that an individual is who she/he is ... make use of a person,s unique physical characteristics, such as ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a leader ... announced the launch of a TR-FRET (time resolved ... Transcreener UDP Assay, a high throughput screening assay ... assay will allow for sensitive detection of hundreds ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... For his creative work in evolutionary systems biology, Jeff ... Technology, is The Pew Charitable Trusts, biomedical researcher of the month. Gore ... the goal of understanding how pathogens become resistant to drugs. ... Inspired ...
... is available in German . ... previously assumed. More precise tests may allow allergy sufferers more freedom ... studies carried out by the Helmholtz Centre for Environmental Research (UFZ), ... The researchers examined patients with a Nile perch allergy. Being allergic ...
... on the biochemical makeup of small interfering RNA ... used in research to help scientists better understand ... accessible to researchers worldwide increases the potential of ... National Center for Advancing Translational Sciences (NCATS) collaborated ...
Cached Biology News:Each food fish can cause specific allergies 2Each food fish can cause specific allergies 3Gene-silencing data now publicly available to help scientists better understand disease 2Gene-silencing data now publicly available to help scientists better understand disease 3
... Super Sensitive MultiLink IHC Detection ... secondary antibodies, labeled with multiple ... the bound primary antibody, and ... Streptavidin-Enzyme conjugate. This kit is ...
Sf21 Insect Cells (Live) in Max-XP Medium...
EZ-DeWax is a one-step solution that simultanously removes paraffin from and rehydrates formalin-fixed, paraffin embedded tissue...
... unit is an inexpensive personal or mini thermal ... process. Lightweight, with a small footprint, it can ... the researcher's desk. , The Gene Cycler thermal ... not have access to a large laboratory thermal ...
Biology Products: